CN113842360A - Eye drops containing moxifloxacin hydrochloride and preparation method thereof - Google Patents
Eye drops containing moxifloxacin hydrochloride and preparation method thereof Download PDFInfo
- Publication number
- CN113842360A CN113842360A CN202111318788.7A CN202111318788A CN113842360A CN 113842360 A CN113842360 A CN 113842360A CN 202111318788 A CN202111318788 A CN 202111318788A CN 113842360 A CN113842360 A CN 113842360A
- Authority
- CN
- China
- Prior art keywords
- eye drops
- moxifloxacin hydrochloride
- feed liquid
- injection
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 41
- 229940012356 eye drops Drugs 0.000 title claims abstract description 35
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 title claims abstract description 35
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000008215 water for injection Substances 0.000 claims abstract description 17
- 239000011780 sodium chloride Substances 0.000 claims abstract description 12
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004327 boric acid Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 21
- 238000001816 cooling Methods 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 229920001684 low density polyethylene Polymers 0.000 claims description 4
- 239000004702 low-density polyethylene Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000010979 pH adjustment Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 238000001228 spectrum Methods 0.000 abstract description 4
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- 239000002699 waste material Substances 0.000 abstract description 3
- 206010014801 endophthalmitis Diseases 0.000 abstract 1
- 230000003204 osmotic effect Effects 0.000 description 4
- 229960003702 moxifloxacin Drugs 0.000 description 3
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000008025 hordeolum Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 239000003306 quinoline derived antiinfective agent Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses moxifloxacin hydrochloride eye drops and a preparation method thereof, wherein the moxifloxacin hydrochloride eye drops comprise the following raw materials in parts by weight: 0.5-0.55 part of moxifloxacin hydrochloride, 0.48-0.5 part of boric acid, 0.3-0.35 part of sodium chloride, 0.4-0.55 part of pH regulator and the balance of water for injection to 100 parts. The preparation method of the moxifloxacin hydrochloride eye drops is simple, and the prepared moxifloxacin hydrochloride eye drops have the characteristics of high efficiency, low toxicity, wide antibacterial spectrum, good stability and the like, and can effectively treat the ophthalmia; the eye drops are filled aseptically, so that the drug pollution risk is reduced, the service life of the eye drops is prolonged, the drug waste is avoided, and the components of the eye drops are simple.
Description
Technical Field
The invention relates to the technical field of eye drops, in particular to an eye drop containing moxifloxacin hydrochloride and a preparation method thereof.
Background
Moxifloxacin is a fourth-generation fluoroquinolone antibiotic, the original manufacturer is German Bayer company, the antibiotic is wider than the former three-generation quinolone drugs and has the trade name 'bayfule', and moxifloxacin has the spectrum antibacterial activity in vitro on gram-positive bacteria, gram-negative bacteria, anaerobic bacteria, acid-fast bacteria and atypical microorganisms such as mycoplasma, chlamydia and legionella. The antibacterial mechanism is interference with II and IV topoisomerase. Topoisomerase is a key enzyme in the control of DNA topology and DNA replication, repair and transcription. Moxifloxacin has high in vivo activity.
As is well known, moxifloxacin hydrochloride eye drops are eye drops of broad-spectrum antibiotics, which are antibiotics and are mainly used for treating keratitis, conjunctivitis, blepharitis and hordeolum. However, the existing moxifloxacin hydrochloride-containing eye drops have general stability and strong irritation in the using process, and therefore, the moxifloxacin hydrochloride eye drops and the preparation method thereof are provided for solving the problems.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides moxifloxacin hydrochloride eye drops and a preparation method thereof, and aims to solve the problems in the background art.
In order to achieve the purpose, the invention provides the following technical scheme: the moxifloxacin hydrochloride eye drops comprise the following raw materials in parts by weight: 0.5-0.55 part of moxifloxacin hydrochloride, 0.48-0.5 part of boric acid, 0.3-0.35 part of sodium chloride, 0.4-0.55 part of pH regulator and the balance of water for injection to 100 parts.
The pH regulator is 1mol/L sodium hydroxide solution.
The pH value is 6.6-7.0, and the preferable pH value is 6.8.
The preparation method of the moxifloxacin hydrochloride eye drops comprises the following steps:
(1) adding 80% of water for injection into the preparation tank, and cooling the water for injection to 15-35 deg.C;
(2) adding boric acid with a formula amount, and stirring until the solution is clear, wherein the stirring speed is 1000-1200 r/min;
(3) adding moxifloxacin hydrochloride with a prescription amount, and stirring until a clear solution is observed, wherein the stirring speed is 1000-1200 r/min;
(4) and (3) pH adjustment: adjusting the pH of the mixed solution to 6.6-7 by using 1mol/L sodium hydroxide solution;
(5) adding sodium chloride according to the formula amount, and stirring until the solution is observed to be clear, wherein the stirring speed is 1000-1200 r/min;
(6) and (3) volume fixing: cooling the rest water for injection to 15-35 deg.C, adding to constant volume, stirring to uniform volume;
(7) roughly filtering the feed liquid in the preparation tank through a 0.45-micrometer PES cylinder filter element through a liquid conveying pipeline, then feeding the feed liquid into a storage tank 1, filtering the feed liquid after rough filtration through a 0.22-micrometer PES cylinder filter element, then feeding the feed liquid into a storage tank 2, and finally sterilizing and filtering the feed liquid after secondary filtration through a 0.22-micrometer PES cylinder filter element to a filling buffer tank;
(8) filling the low-density polyethylene medicinal eye drop bottle into the can under the aseptic environment, wherein the filling speed is 60-90 per minute, and the content of each bottle is 5.0-5.3 ml.
Wherein the purpose of adding sodium chloride is to adjust osmotic pressure, and the osmotic pressure is adjusted to 290-310 mOsm/L; before and after filling and sealing, the bubble point of the PES sterilizing and filtering filter element with the diameter of 0.22 mu m is required to be more than or equal to 0.32 MPa.
Compared with the prior art, the invention provides moxifloxacin hydrochloride eye drops and a preparation method thereof, and the moxifloxacin hydrochloride eye drops have the following beneficial effects:
1. the moxifloxacin hydrochloride eye drops prepared by the invention have the characteristics of high efficiency, low toxicity, wide antibacterial spectrum, good stability and the like, and can effectively treat ocular inflammation.
2. The eye drops are filled aseptically, so that the drug pollution risk is reduced, the service life of the eye drops is prolonged, the drug waste is avoided, and the components of the eye drops are simple.
Drawings
FIG. 1 is a flow chart of an eye drop containing moxifloxacin hydrochloride and a preparation method thereof.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The moxifloxacin hydrochloride eye drops comprise the following raw materials in parts by weight: 0.52 part of moxifloxacin hydrochloride, 0.49 part of boric acid, 0.32 part of sodium chloride, 0.45 part of 1mol/L sodium hydroxide solution and the balance of water for injection to 100 parts.
The preparation method of the moxifloxacin hydrochloride eye drops comprises the following steps:
(1) adding 80% of water for injection into the preparation tank, and cooling the water for injection to 25 deg.C;
(2) adding a prescribed amount of boric acid, and stirring until the solution is observed to be clear, wherein the stirring speed is 1100 r/min;
(3) adding the moxifloxacin hydrochloride with the prescription amount, and stirring until the solution is observed to be clear, wherein the stirring speed is 1100 r/min;
(4) and (3) pH adjustment: adjusting the pH of the mixed solution to 6.7 by using 1mol/L sodium hydroxide solution;
(5) adding sodium chloride according to the prescription amount, and stirring until the solution is observed to be clear, wherein the stirring speed is 1100 r/min;
(6) and (3) volume fixing: cooling the rest water for injection to 25 deg.C, adding to constant volume, stirring to uniform volume;
(7) roughly filtering the feed liquid in the preparation tank through a 0.45-micrometer PES cylinder filter element through a liquid conveying pipeline, then feeding the feed liquid into a storage tank 1, filtering the feed liquid after rough filtration through a 0.22-micrometer PES cylinder filter element, then feeding the feed liquid into a storage tank 2, and finally sterilizing and filtering the feed liquid after secondary filtration through a 0.22-micrometer PES cylinder filter element to a filling buffer tank;
(8) and filling the low-density polyethylene medicinal eye drop bottle into the can under the aseptic environment, wherein the filling speed is 60-90 per minute, and the content of each bottle is 5.0 ml.
Wherein the sodium chloride is added for the purpose of regulating the osmotic pressure to 305 mOsm/L; before and after filling and sealing, the bubble point of the PES sterilizing and filtering filter element with the diameter of 0.22 mu m is required to be more than or equal to 0.32 MPa.
Example 2
The moxifloxacin hydrochloride eye drops comprise the following raw materials in parts by weight: 0.545 part of moxifloxacin hydrochloride, 0.5 part of boric acid, 0.34 part of sodium chloride, 0.52 part of 1mol/L sodium hydroxide solution and the balance of water for injection to 100 parts.
The preparation method of the moxifloxacin hydrochloride eye drops comprises the following steps:
(1) adding 80% of water for injection into the preparation tank, and cooling the water for injection to 28 deg.C;
(2) adding a prescribed amount of boric acid, and stirring until the solution is observed to be clear, wherein the stirring speed is 1200 revolutions per minute;
(3) adding the moxifloxacin hydrochloride with the prescription amount, and stirring until the solution is observed to be clear, wherein the stirring speed is 1200 r/min;
(4) and (3) pH adjustment: adjusting the pH of the mixed solution to 6.8 by using 1mol/L sodium hydroxide solution;
(5) adding sodium chloride according to the prescription amount, and stirring until the solution is observed to be clear, wherein the stirring speed is 1200 revolutions per minute;
(6) and (3) volume fixing: cooling the rest water for injection to 28 deg.C, adding to constant volume, stirring to uniform volume;
(7) roughly filtering the feed liquid in the preparation tank through a 0.45-micrometer PES cylinder filter element through a liquid conveying pipeline, then feeding the feed liquid into a storage tank 1, filtering the feed liquid after rough filtration through a 0.22-micrometer PES cylinder filter element, then feeding the feed liquid into a storage tank 2, and finally sterilizing and filtering the feed liquid after secondary filtration through a 0.22-micrometer PES cylinder filter element to a filling buffer tank;
(8) and filling the low-density polyethylene medicinal eye drop bottle into the can under the aseptic environment, wherein the filling speed is 60-90 per minute, and the content of each bottle is 5.0 ml.
Wherein the sodium chloride is added for the purpose of regulating the osmotic pressure to 300 mOsm/L; before and after filling and sealing, the bubble point of the PES sterilizing and filtering filter element with the diameter of 0.22 mu m is required to be more than or equal to 0.32 MPa.
The moxifloxacin hydrochloride eye drops prepared by the invention have the characteristics of high efficiency, low toxicity, wide antibacterial spectrum, good stability and the like, and can effectively treat ocular inflammation. The eye drops are filled aseptically, so that the drug pollution risk is reduced, the service life of the eye drops is prolonged, the drug waste is avoided, and the components of the eye drops are simple.
Embodiments of the present invention will be understood to those skilled in the art to which the present invention pertains that various changes, modifications, substitutions, and alterations can be made without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.
Claims (4)
1. The moxifloxacin hydrochloride eye drops are characterized by comprising the following raw materials in parts by weight: 0.5-0.55 part of moxifloxacin hydrochloride, 0.48-0.5 part of boric acid, 0.3-0.35 part of sodium chloride, 0.4-0.55 part of pH regulator and the balance of water for injection to 100 parts.
2. The moxifloxacin hydrochloride eye drops as claimed in claim 1, is characterized in that: the pH regulator is 1mol/L sodium hydroxide solution.
3. The moxifloxacin hydrochloride eye drops as claimed in claim 1, is characterized in that: the pH value is 6.6-7.0, and the preferable pH value is 6.8.
4. The method for preparing moxifloxacin hydrochloride eye drops as claimed in any one of claims 1 to 3, characterized in that the preparation process comprises:
(1) adding 80% of water for injection into the preparation tank, and cooling the water for injection to 15-35 deg.C;
(2) adding boric acid with a formula amount, and stirring until the solution is clear, wherein the stirring speed is 1000-1200 r/min;
(3) adding moxifloxacin hydrochloride with a prescription amount, and stirring until a clear solution is observed, wherein the stirring speed is 1000-1200 r/min;
(4) and (3) pH adjustment: adjusting the pH of the mixed solution to 6.6-7.0 by using 1mol/L sodium hydroxide solution;
(5) adding sodium chloride according to the formula amount, and stirring until the solution is observed to be clear, wherein the stirring speed is 1000-1200 r/min;
(6) and (3) volume fixing: cooling the rest water for injection to 15-35 deg.C, adding to constant volume, stirring to uniform volume;
(7) roughly filtering the feed liquid in the preparation tank through a 0.45-micrometer PES cylinder filter element through a liquid conveying pipeline, then feeding the feed liquid into a storage tank 1, filtering the feed liquid after rough filtration through a 0.22-micrometer PES cylinder filter element, then feeding the feed liquid into a storage tank 2, and finally sterilizing and filtering the feed liquid after secondary filtration through a 0.22-micrometer PES cylinder filter element to a filling buffer tank;
(8) filling the low-density polyethylene medicinal eye drop bottle into the can under the aseptic environment, wherein the filling speed is 60-90 per minute, and the content of each bottle is 5.0-5.3 ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111318788.7A CN113842360A (en) | 2021-11-09 | 2021-11-09 | Eye drops containing moxifloxacin hydrochloride and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111318788.7A CN113842360A (en) | 2021-11-09 | 2021-11-09 | Eye drops containing moxifloxacin hydrochloride and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113842360A true CN113842360A (en) | 2021-12-28 |
Family
ID=78983947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111318788.7A Pending CN113842360A (en) | 2021-11-09 | 2021-11-09 | Eye drops containing moxifloxacin hydrochloride and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113842360A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116139077A (en) * | 2022-12-28 | 2023-05-23 | 江苏广承药业有限公司 | Moxifloxacin hydrochloride eye drops |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103181892A (en) * | 2013-02-20 | 2013-07-03 | 南京恒道医药科技有限公司 | Moxifloxacin hydrochloride eye drops and preparation method thereof |
| US20200155766A1 (en) * | 2017-04-14 | 2020-05-21 | Nal Pharmaceutical Group Limited | Pre-filled syringe containing moxifloxacin |
| CN113288866A (en) * | 2021-07-12 | 2021-08-24 | 山东诺明康药物研究院有限公司 | Antibacterial eye drops and preparation method thereof |
-
2021
- 2021-11-09 CN CN202111318788.7A patent/CN113842360A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103181892A (en) * | 2013-02-20 | 2013-07-03 | 南京恒道医药科技有限公司 | Moxifloxacin hydrochloride eye drops and preparation method thereof |
| US20200155766A1 (en) * | 2017-04-14 | 2020-05-21 | Nal Pharmaceutical Group Limited | Pre-filled syringe containing moxifloxacin |
| CN113288866A (en) * | 2021-07-12 | 2021-08-24 | 山东诺明康药物研究院有限公司 | Antibacterial eye drops and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 董根山等: "盐酸莫西沙星滴眼液的制备与质量控制", 《医药导报》 * |
| 黄依沙: "盐酸莫西沙星滴眼液的研制和质量研究", 《中国优秀硕士学位论文全文数据库工程科技Ⅰ辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116139077A (en) * | 2022-12-28 | 2023-05-23 | 江苏广承药业有限公司 | Moxifloxacin hydrochloride eye drops |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Oxygen‐Carrying and Antibacterial Fluorinated Nano‐Hydroxyapatite Incorporated Hydrogels for Enhanced Bone Regeneration | |
| CN113842360A (en) | Eye drops containing moxifloxacin hydrochloride and preparation method thereof | |
| CN103740790B (en) | A kind of production method improving Yield of Neomycin | |
| CN103550143A (en) | Preparation method of levetiracetam injection | |
| CN108853016A (en) | A kind of ophthalmic solution sodium eye drops and preparation method thereof | |
| CN111172231B (en) | Method for checking limitation of voriconazole microorganisms | |
| KR102075173B1 (en) | Bromfenac aqueous liquid composition having preservative efficiency | |
| CN117205151A (en) | Amikacin sulfate injection and preparation method thereof | |
| CN105287371B (en) | A kind of pazufloxacin mesylate injection composition and preparation method thereof | |
| CN105232449A (en) | Moxifloxacin hydrochloride sodium hyaluronate controlled-release nanogel and preparation method thereof | |
| CN111110627B (en) | Amikacin sulfate injection and preparation method thereof | |
| CN108939172B (en) | Degradable material for disposable uterine probe | |
| CN102046173B (en) | Aqueous liquid containing gatifloxacin, method for production thereof, and method for prevention of production of precipitates during storage of the aqueous liquid at low temperature or upon freezing/thawing of the aqueous liquid | |
| CN105232452A (en) | Bacteriostat-free ofloxacin eye drops and preparation process thereof | |
| CN115521968A (en) | Microbial limit detection method for moxifloxacin hydrochloride raw material | |
| CN105982843A (en) | Preparation method of moxifloxacin hydrochloride chitosan eye-use gel | |
| CN104173291A (en) | Method for controlling related substances in cefodizime sodium | |
| CN103720641A (en) | Taurine-containing ophthalmic in-vivo gel preparation and preparation method thereof | |
| CN105523687B (en) | The sulfur removal technology of battery waste water | |
| CN117503697A (en) | Moxifloxacin hydrochloride eye drops and preparation method thereof | |
| CN101884621B (en) | Preparation method of salinomycin particle premix | |
| CN117562856A (en) | Moxifloxacin hydrochloride eye drops and preparation method thereof | |
| CN113429080A (en) | Process for treating wastewater generated in sulfamonomethoxine production | |
| CN110934825A (en) | Citicoline injection and preparation method thereof | |
| CN102743760B (en) | Bacteriostatic agent GellanGum-containing externally-used composite for eyes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211228 |
|
| RJ01 | Rejection of invention patent application after publication |